These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

218 related items for PubMed ID: 38463543

  • 1. Efficacy and Safety of HepaSphere Drug-Eluting Bead Transarterial Chemoembolization Combined with Hepatic Arterial Infusion Chemotherapy as the Second-Line Treatment in Advanced Hepatocellular Carcinoma.
    Liu B, Gao S, Guo J, Kou F, Liu S, Zhang X, Feng A, Wang X, Cao G, Chen H, Liu P, Xu H, Gao Q, Yang R, Xu L, Zhu X.
    J Hepatocell Carcinoma; 2024; 11():477-488. PubMed ID: 38463543
    [Abstract] [Full Text] [Related]

  • 2. Lenvatinib plus drug-eluting bead transarterial chemoembolization with/without hepatic arterial infusion chemotherapy for hepatocellular carcinoma larger than 7 cm with major portal vein tumor thrombosis: a multicenter retrospective cohort study.
    Cai M, Liang L, Zhang J, Chen N, Huang W, Guo Y, Hong X, Lin L, Liu Y, Dan C, Deng H, Liu X, Zhou J, Chen Y, Chen H, Zhu K.
    Int J Surg; 2024 Jun 13; 110(12):7860-70. PubMed ID: 38869974
    [Abstract] [Full Text] [Related]

  • 3. Drug-Eluting Bead Transarterial Chemoembolization Combined with FOLFOX-Based Hepatic Arterial Infusion Chemotherapy for Large or Huge Hepatocellular Carcinoma.
    Huang J, Huang W, Zhan M, Guo Y, Liang L, Cai M, Lin L, He M, Lian H, Lu L, Zhu K.
    J Hepatocell Carcinoma; 2021 Jun 13; 8():1445-1458. PubMed ID: 34858889
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of hepatic arterial infusion chemotherapy combined with transarterial embolization for unresectable hepatocellular carcinoma: A propensity score-matching cohort study.
    Guo W, Gao J, Zhuang W, Wu Z, Li B, Chen S.
    JGH Open; 2020 Jun 13; 4(3):477-483. PubMed ID: 32514457
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of hepatic artery infusion chemotherapy combined with tyrosine kinase inhibitors plus programmed death-1 inhibitors for hepatocellular carcinoma refractory to transarterial chemoembolization.
    Lin LW, Ke K, Yan LY, Chen R, Huang JY.
    Front Oncol; 2023 Jun 13; 13():1178428. PubMed ID: 37207144
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors versus lenvatinib and PD-1 inhibitors for HCC refractory to TACE.
    Diao L, Wang C, You R, Leng B, Yu Z, Xu Q, Cheng Y, Yin G.
    J Gastroenterol Hepatol; 2024 Apr 13; 39(4):746-753. PubMed ID: 38240156
    [Abstract] [Full Text] [Related]

  • 11. Hepatic arterial infusion chemotherapy for hepatocellular carcinoma refractory to transarterial chemoembolization: exploring the influence of prior transarterial chemoembolization and additional transarterial chemoembolization on survival outcomes.
    Hien PN, Chun HJ, Oh JS, Kim SH, Choi BG.
    J Gastrointest Oncol; 2024 Apr 30; 15(2):721-729. PubMed ID: 38756625
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Sorafenib combined with embolization plus hepatic arterial infusion chemotherapy for inoperable hepatocellular carcinoma.
    Liu BJ, Gao S, Zhu X, Guo JH, Zhang X, Chen H, Wang XD, Yang RJ.
    World J Gastrointest Oncol; 2020 Jun 15; 12(6):663-676. PubMed ID: 32699581
    [Abstract] [Full Text] [Related]

  • 14. High-Risk Hepatocellular Carcinoma: Hepatic Arterial Infusion Chemotherapy versus Transarterial Chemoembolization.
    Zhang B, Huang B, Yang F, Yang J, Kong M, Wang J, Xiang Y, Wang K, Peng R, Yang K, An C, Yan D.
    J Hepatocell Carcinoma; 2024 Jun 15; 11():651-663. PubMed ID: 38559554
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Infiltrative Hepatocellular Carcinoma: Transcatheter Arterial Chemoembolization Versus Hepatic Arterial Infusion Chemotherapy.
    An C, Zuo M, Li W, Chen Q, Wu P.
    Front Oncol; 2021 Jun 15; 11():747496. PubMed ID: 34976800
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Hepatic artery infusion chemotherapy using mFOLFOX versus transarterial chemoembolization for massive unresectable hepatocellular carcinoma: a prospective non-randomized study.
    He MK, Le Y, Li QJ, Yu ZS, Li SH, Wei W, Guo RP, Shi M.
    Chin J Cancer; 2017 Oct 23; 36(1):83. PubMed ID: 29061175
    [Abstract] [Full Text] [Related]

  • 19. Transarterial chemoembolization using drug-eluting beads versus lipiodol in the treatment of unresectable hepatocellular carcinoma: propensity score matching.
    Cao G, Gu J, Zhang H, Ji W, Zhu D, Bao Y, Asi H, Ren W.
    J Gastrointest Oncol; 2024 Jun 30; 15(3):1101-1111. PubMed ID: 38989437
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of transcatheter arterial chemoembolization plus hepatic arterial infusion chemotherapy in the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombosis in the main trunk.
    Wu Z, Gao J, Zhuang W, Yang J, Guo W.
    J Cancer Res Ther; 2022 Apr 30; 18(2):345-351. PubMed ID: 35645099
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.